Trial watch: DNA-based vaccines for oncological indications

doi:10.1080/2162402X.2017.1398878

Review

. 2017 Nov 20;6(12):e1398878.

doi: 10.1080/2162402X.2017.1398878. eCollection 2017.

Trial watch: DNA-based vaccines for oncological indications

Stefano Pierini^{1

2}, Renzo Perales-Linares^{1

2}, Mireia Uribe-Herranz^{1

2}, Jonathan G Pol^{3

4

5

6}, Laurence Zitvogel^{7

8

9

10}, Guido Kroemer^{3

4

5

6

11

12

13}, Andrea Facciabene^{1

2}, Lorenzo Galluzzi^{3

14

15}

Affiliations

¹ Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Ovarian Cancer Research Center (OCRC), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Université Paris Descartes/Paris V, France.
⁴ Université Pierre et Marie Curie/Paris VI, Paris.
⁵ Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
⁶ INSERM, Paris, France.
⁷ Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
⁸ INSERM, Villejuif, France.
⁹ Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Villejuif, France.
¹⁰ Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France.
¹¹ Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
¹² Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
¹³ Pôle de Biologie, Hopitâl Européen George Pompidou, AP-HP; Paris, France.
¹⁴ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
¹⁵ Sandra and Edward Meyer Cancer Center, New York, NY, USA.

PMID: 29209575
PMCID: PMC5706602
DOI: 10.1080/2162402X.2017.1398878

Review

Trial watch: DNA-based vaccines for oncological indications

Stefano Pierini et al. Oncoimmunology. 2017.

. 2017 Nov 20;6(12):e1398878.

doi: 10.1080/2162402X.2017.1398878. eCollection 2017.

Authors

Affiliations

¹ Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Ovarian Cancer Research Center (OCRC), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Université Paris Descartes/Paris V, France.
⁴ Université Pierre et Marie Curie/Paris VI, Paris.
⁵ Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
⁶ INSERM, Paris, France.
⁷ Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
⁸ INSERM, Villejuif, France.
⁹ Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Villejuif, France.
¹⁰ Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France.
¹¹ Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
¹² Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
¹³ Pôle de Biologie, Hopitâl Européen George Pompidou, AP-HP; Paris, France.
¹⁴ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
¹⁵ Sandra and Edward Meyer Cancer Center, New York, NY, USA.

PMID: 29209575
PMCID: PMC5706602
DOI: 10.1080/2162402X.2017.1398878

Abstract

DNA-based vaccination is a promising approach to cancer immunotherapy. DNA-based vaccines specific for tumor-associated antigens (TAAs) are indeed relatively simple to produce, cost-efficient and well tolerated. However, the clinical efficacy of DNA-based vaccines for cancer therapy is considerably limited by central and peripheral tolerance. During the past decade, considerable efforts have been devoted to the development and characterization of novel DNA-based vaccines that would circumvent this obstacle. In this setting, particular attention has been dedicated to the route of administration, expression of modified TAAs, co-expression of immunostimulatory molecules, and co-delivery of immune checkpoint blockers. Here, we review preclinical and clinical progress on DNA-based vaccines for cancer therapy.

Keywords: CTLA4; PADRE; PD-1; TRICOM; adenovirus; cancer testis antigens; electroporation.

PubMed Disclaimer

Cited by

Trial watch: Peptide-based vaccines in anticancer therapy.
Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Bezu L, et al. Oncoimmunology. 2018 Sep 6;7(12):e1511506. doi: 10.1080/2162402X.2018.1511506. eCollection 2018. Oncoimmunology. 2018. PMID: 30524907 Free PMC article. Review.
Application of Plasmid Engineering to Enhance Yield and Quality of Plasmid for Vaccine and Gene Therapy.
Folarin O, Nesbeth D, Ward JM, Keshavarz-Moore E. Folarin O, et al. Bioengineering (Basel). 2019 Jun 19;6(2):54. doi: 10.3390/bioengineering6020054. Bioengineering (Basel). 2019. PMID: 31248216 Free PMC article.
DNA Vaccines-How Far From Clinical Use?
Hobernik D, Bros M. Hobernik D, et al. Int J Mol Sci. 2018 Nov 15;19(11):3605. doi: 10.3390/ijms19113605. Int J Mol Sci. 2018. PMID: 30445702 Free PMC article. Review.
Preclinical study of a DNA vaccine targeting SARS-CoV-2.
Hayashi H, Sun J, Yanagida Y, Otera T, Kubota-Koketsu R, Shioda T, Ono C, Matsuura Y, Arase H, Yoshida S, Nakamaru R, Ju N, Ide R, Tenma A, Kawabata S, Ehara T, Sakaguchi M, Tomioka H, Shimamura M, Okamoto S, Amaishi Y, Chono H, Mineno J, Komatsuno T, Saito Y, Rakugi H, Morishita R, Nakagami H. Hayashi H, et al. Curr Res Transl Med. 2022 Sep;70(4):103348. doi: 10.1016/j.retram.2022.103348. Epub 2022 Apr 20. Curr Res Transl Med. 2022. PMID: 35489099 Free PMC article.
Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers.
Kandalaft LE, Harari A. Kandalaft LE, et al. Cancers (Basel). 2021 Nov 19;13(22):5819. doi: 10.3390/cancers13225819. Cancers (Basel). 2021. PMID: 34830973 Free PMC article. Review.

See all "Cited by" articles

References

1. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005;18:21–5. - PMC - PubMed
1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–70. doi:10.1126/science.1203486. - DOI - PubMed
1. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al.. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472–508. doi:10.18632/oncotarget.2998. - DOI - PMC - PubMed
1. Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, et al.. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e985940. doi:10.4161/2162402X.2014.985940. PMID:25949870. - DOI - PMC - PubMed
1. Chaganty BK, Lu Y, Qiu S, Somanchi SS, Lee DA, Fan Z. Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNgamma secretion. Oncoimmunology. 2016;5:e1100790. doi:10.1080/2162402X.2015.1100790. PMID:27141382. - DOI - PMC - PubMed

Publication types

Actions
Actions

Grants and funding

R01 CA206012/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

[1] Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005;18:21–5. - PMC - PubMed

[2] Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005;18:21–5. - PMC - PubMed

[3] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–70. doi:10.1126/science.1203486. - DOI - PubMed

[4] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–70. doi:10.1126/science.1203486. - DOI - PubMed

[5] Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al.. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472–508. doi:10.18632/oncotarget.2998. - DOI - PMC - PubMed

[6] Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al.. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472–508. doi:10.18632/oncotarget.2998. - DOI - PMC - PubMed

[7] Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, et al.. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e985940. doi:10.4161/2162402X.2014.985940. PMID:25949870. - DOI - PMC - PubMed

[8] Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, et al.. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e985940. doi:10.4161/2162402X.2014.985940. PMID:25949870. - DOI - PMC - PubMed

[9] Chaganty BK, Lu Y, Qiu S, Somanchi SS, Lee DA, Fan Z. Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNgamma secretion. Oncoimmunology. 2016;5:e1100790. doi:10.1080/2162402X.2015.1100790. PMID:27141382. - DOI - PMC - PubMed

[10] Chaganty BK, Lu Y, Qiu S, Somanchi SS, Lee DA, Fan Z. Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNgamma secretion. Oncoimmunology. 2016;5:e1100790. doi:10.1080/2162402X.2015.1100790. PMID:27141382. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Trial watch: DNA-based vaccines for oncological indications

Affiliations

Trial watch: DNA-based vaccines for oncological indications

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous